Cart
sales@molnova.com
Matuzumab
CAS No. 339186-68-4
Matuzumab( —— )
Catalog No. M22153 CAS No. 339186-68-4
Matuzumab is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR frequently associated with the growth of blood vessels in malignancy facilitating tumor growth and survival.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 516 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMatuzumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionMatuzumab is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR frequently associated with the growth of blood vessels in malignancy facilitating tumor growth and survival.
-
DescriptionMatuzumab is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR frequently associated with the growth of blood vessels in malignancy facilitating tumor growth and survival.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number339186-68-4
-
Formula Weight——
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Rob C. Roovers, et al. A bi-paratopic anti-EGFR nanobody efficiently inhibits solid tumour growth.Int J Cancer. 2011 Oct 15; 129(8): 2013–2024.
molnova catalog
related products
-
WAY-270360
WAY-270360 is a sirtuin modulator and an epidermal growth factor receptor (EGFR) inhibitor.
-
Glaucocalyxin A
Glaucocalyxin A-SBE-β-CD could be useful with a better solubility and sustained function in drug delivery.
-
BI-4020
BI-4020 is a fourth-generation, non-covalent, and orally active inhibitor of EGFR tyrosine kinase.
